ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma.International journal of hematology · 2026Article
- Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.Annals of medicine · 2025Article
- Article
- A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.Oncology research · 2025Review
- Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA.Frontiers in oncology · 2025Article
- Article
- Article
- Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma.Blood advances · 2024Article
- More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.Annals of hematology · 2023Article
- More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients.Frontiers in oncology · 2023Review
- "Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.Frontiers in oncology · 2022Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35759726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.